drugset / Trial / NCT00126399

A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea

NCT00126399

Phase 3 Completed 528 enrolled CollaGenex Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the safety and efficacy of 40 mg doxycycline controlled-release capsules administered once daily for the treatment of rosacea compared with a placebo.

Timeline

Start
2004-06
Primary completion
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 40 mg

Indications